Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788280 | 1.00 | LMNA (0.65) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL391547 | 0.95 | MEN1 (0.71) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL183994 | 0.92 | LMNA (0.70) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL2256044 | 0.90 | SMPD1 (0.59) | LMNAHPGDKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3129603 | 0.88 | MEN1 (0.74) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL29475634 | 0.88 | LMNA (0.69) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL90412 | 0.88 | LMNA (0.69) | LMNAHPGDKMT2AMEN1MAOB | |
| SCHEMBL29788233 | 0.88 | MEN1 (0.84) | KMT2AMEN1MAOBMRGPRX4GAA | |
| SCHEMBL340452 | 0.88 | MEN1 (0.84) | KMT2AMEN1MAOBMRGPRX4GAA | |
| SCHEMBL620242 | 0.88 | LMNA (0.54) | LMNAHPGDKMT2AMEN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583507-B2 | Direct AMPK activator compounds | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-02-21 | — | — | US | disclosed |
| US-11583507-B2 | Direct AMPK activator compounds | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-02-21 | — | — | US | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3968976-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-20220062199-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-113784708-A | Phenanthrene AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| EP-3801475-A1 | DIRECT AMPK ACTIVATOR COMPOUNDS | Société des Produits Nestlé S.A. (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-20210038536-A1 | DIRECT AMPK ACTIVATOR COMPOUNDS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-02-11 | — | — | US | disclosed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | LMNA 4358/4885HPGD 1033/4885KMT2A 4423/4885 |
| US-11583507-B2 | Direct AMPK activator compounds | PRKAG2, AK2, PRKAG3 | LMNA 2183/4885HPGD 2285/4885KMT2A 1673/4885 |
| US-20210038536-A1 | DIRECT AMPK ACTIVATOR COMPOUNDS | PRKAG2, AK2, PRKAG3 | LMNA 2183/4885HPGD 2285/4885KMT2A 1673/4885 |
| US-20220062199-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | PRKAG2, PRKAG1, PRKAG3 | LMNA 1860/4885HPGD 827/4885KMT2A 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.